Therapeutic area
Women's health & fertility
Early gestational diabetes: does diagnosis and treatment before 20 weeks change outcomes?
Two 2025 meta-analyses of randomized trials found no consistent benefit from treating gestational diabetes diagnosed before 20 weeks, apart from secondary outcomes such as less neonatal respiratory distress.
Menopausal hormone therapy: what the 2025-26 labeling change removes and what it keeps
In November 2025 the FDA asked for cardiovascular disease, breast cancer and probable dementia language to come out of the boxed warning on menopausal hormone therapy, and had approved revised labels for six products by February 2026.
Self-collected HPV testing for cervical screening: what the 2025-26 guidance now allows
In the 2025 consensus and 2026 ACS guidance, self-collected vaginal HPV tests are acceptable for average-risk screening with a 3-year repeat interval after a negative result, while the not-yet-final USPSTF draft lists 5 years.